CYP2C9抗体

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P08194(CYP2C9 Antibody) at dilution 1/50. (Original magnification: ×200)    

  
  

The cytochrome P450 2C9 (CYP2C9) enzyme, part of the CYP450 superfamily, plays a critical role in metabolizing approximately 15-20% of clinically prescribed drugs, including warfarin, phenytoin, and NSAIDs, as well as endogenous compounds like steroids. Genetic polymorphisms in the *CYP2C9* gene significantly influence enzyme activity, leading to interindividual variability in drug metabolism and therapeutic outcomes. Over 60 variant alleles have been identified, with *CYP2C9*2 and *CYP2C9*3 being the most clinically relevant, associated with reduced enzymatic function and increased risk of adverse drug reactions.

CYP2C9 antibodies are essential tools for studying enzyme expression, localization, and activity in tissues. They enable detection of protein levels in liver samples, aiding pharmacogenomic research to correlate genotype-phenotype relationships. Such antibodies also support diagnostic assays to identify poor metabolizers, guiding personalized dosing strategies. In drug development, they help assess CYP2C9-mediated drug interactions by identifying inhibitors or inducers.

Challenges in CYP2C9 antibody applications include cross-reactivity with homologous CYP isoforms (e.g., CYP2C19) and variability in assay standardization. Recent advances in monoclonal antibody engineering aim to improve specificity. Ongoing research focuses on elucidating structure-function relationships and ethnic-specific allele distributions to refine precision medicine approaches. Collaborative efforts between pharmacologists, clinicians, and biotechnologists remain crucial to optimize CYP2C9 antibody utility in translational research and clinical practice.